Ryan A Lacinski, Sebastian A Dziadowicz, Amanda Stewart, Edwin Chaharbakhshi, Halima Akhter, John J Pisquiy, Jack H Victory, Joshua B Hardham, Claude Chew, Alyson Prorock, Yongde Bao, Katia Sol-Church, Gerald R Hobbs, Edwin Klein, Michael A Nalesnik, Gangqing Hu, Ana de Oliveira, Stell P Santiago, Brock A Lindsey
Systemic administration of interleukin (IL)-12 induces potent anti-tumor immune responses in preclinical cancer models through the systemic activation of effector immune cells and release of proinflammatory cytokines. IL-12-loaded PLGA nanospheres (IL12ns) are hypothesized to improve therapeutic efficacy and thwart unwanted side effects observed in previous human clinical trials. Through the investigation of peripheral blood and local tissue immune responses in healthy BALB/c mice, the immune-protective pharmacodynamics of IL12ns were suggested...
February 16, 2024: IScience